Background/Aims: This study aims to examine the differences in plasma thiol-disulphide levels that are related to oxidative stress among obese and nonobese women with polycystic ovary syndrome (PCOS) and their age/body mass index (BMI)-matched healthy controls. Methods: The participants were divided into 4 groups based on BMI (nonobese and obese). Serum thiol and disulphide levels were compared among groups. Results: Serum thiols were found higher in the obese PCOS group than those in the obese control group in the study (thiol: 407.33 ± 46.25 vs. 365.67 ± 67.03 µmol/l, p = 0.014). Disulphide levels were observed to be decreased in the obese PCOS group relative to its control (21.39 ± 1.33 vs. 23.53 ± 8.47 µmol/l, p = 0.021). Serum thiol levels were found to be higher in the nonobese PCOS group compared to nonobese controls (thiol: 434.7 ± 46.92 vs. 422.94 ± 46.61 µmol/l, p = 0.031). Significant differences of disulphide levels between the nonobese PCOS group and the nonobese control group were observed (18.07 ± 1.93 vs. 20.68 ± 3.79 µmol/l, p = 0.027). Conclusion: High antioxidant levels in women with PCOS may be related to either mechanisms involving anovulation, multiple follicular development, and apoptosis or to their compensatory system against oxidative load arising from obesity and overweightness.

1.
Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H: Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27:3067-3073.
2.
Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, et al: Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36:691-697.
3.
Verit FF, Erel O: Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest 2008;65:233-239.
4.
Martínez-Bermejo E, Luque-Ramírez M, Escobar-Morreale HF: Obesity and the polycystic ovary syndrome. Minerva Endocrinol 2007;32:129-140.
5.
Go YM, Jones DP: Thiol/disulfide redox states in signaling and sensing. Crit Rev Biochem Mol Biol 2013;48:173-181.
6.
Circu ML, Aw TY: Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010;48:749-762.
7.
Pasaoglu H, Sancak B, Bukan N: Lipid peroxidation and resistance to oxidation in patients with type 2 diabetes mellitus. Tohoku J Exp Med 2004;203:211-218.
8.
Masutani H, Yoshihara E, Masaki S, Chen Z, Yodoi J: Thioredoxin binding protein (TBP)-2/Txnip and α-arrestin proteins in cancer and diabetes mellitus. J Clin Biochem Nutr 2012;50:23-34.
9.
Coskun A, Ercan O, Arikan DC, Özer A, Kilinc M, Kiran G, et al: Modified Ferriman-Gallwey hirsutism score and androgen levels in Turkish women. Eur J Obstet Gynecol Reprod Biol 2011;154:167-171.
10.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
11.
Erel O, Neselioglu S: A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 2014;47:326-332.
12.
Blair SA, Kyaw-Tun T, Young IS, Phelan NA, Gibney J, McEneny J: Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome. J Reprod Med 2013;58:107-114.
13.
Tilly JL, Tilly KI: Inhibitors of oxidative stress mimic the ability of follicle-stimulating hormone to suppress apoptosis in cultured rat ovarian follicles. Endocrinology 1995;136:242-252.
14.
Gupta RK, Miller KP, Babus JK, Flaws JA: Methoxychlor inhibits growth and induces atresia of antral follicles through an oxidative stress pathway. Toxicol Sci 2006;93:382-389.
15.
Cataldo NA, Dumesic DA, Goldsmith PC, Jaffe RB: Immunolocalization of Fas and Fas ligand in the ovaries of women with polycystic ovary syndrome: relationship to apoptosis. Hum Reprod 2000;15:1889-1897.
16.
Tsai-Turton M, Luderer U: Opposing effects of glutathione depletion and follicle-stimulating hormone on reactive oxygen species and apoptosis in cultured preovulatory rat follicles. Endocrinology 2006;147:1224-1236.
17.
Chandra J, Samali A, Orrenius S: Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 2000;29:323-333.
18.
Sabuncu T, Vural H, Harma M, Harma M: Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001;34:407-413.
19.
Vincent HK, Innes KE, Vincent KR: Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab 2007;9:813-839.
20.
Behrman HR, Kodaman PH, Preston SL, Gao S: Oxidative stress and the ovary. J Soc Gynecol Investig 2001;8(1 suppl proceedings):S40-S42.
21.
Ruder EH, Hartman TJ, Goldman MB: Impact of oxidative stress on female fertility. Curr Opin Obstet Gynecol 2009;21:219-222.
22.
Sikaris KA: The clinical biochemistry of obesity. Clin Biochem Rev 2004;25:165-181.
23.
Chrysohoou C, Panagiotakos DB, Pitsavos C, Skoumas I, Papademetriou L, Economou M, et al: The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. Nutr Metab Cardiovasc Dis 2007;17:590-597.
24.
Lim SS, Davies MJ, Norman RJ, Moran LJ: Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012;18:618-637.
25.
Liou TH, Yang JH, Hsieh CH, Lee CY, Hsu CS, Hsu MI: Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril 2009;92:1960-1965.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.